A phase I study investigating BRAF inhibitor encorafenib (LGX818) combined with cetuximab, either with or without PI3K inhibitor alpelisib (BYL719), demonstrated favorable toxicity profiles of both the dual and triple combination with objective response rates of 30 % and disease control rates of 80 and 90 %, respectively, in patients with pretreated advanced BRAFm CRC [28]. Here, PIK3CA is linked to colorectal carcinoma.